Cited by 4,427Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Open access

Greenberg, Peter, Cox, Christopher, LeBeau, Michelle M., Fenaux, Pierre, Morel, Pierre, Sanz, Guillermo, Sanz, Miguel, Vallespi, Teresa, Hamblin, Terry, Oscier, David, Ohyashiki, Kazuma, Toyama, Keisuke, Aul, Carlo, Mufti, Ghulam, Bennett, John·1997·Blood

DOI 10.1182/blood.v89.6.2079

Open this paper in CoChat — free account Open PDF

Abstract

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: “good” outcomes were normal, −Y alone, del(5q) alone, del(20q) alone; “poor” outcomes were complex (ie, ≥3 abnormalities) or chromosome 7 anomalies; and “intermediate” outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood.v89.6.2079

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citation
Myelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Self-citation
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431
Self-citation
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients
Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Self-citation
The 5q− anomaly
BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Self-citation
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
Self-citation
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes
Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246
Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia
Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Show all 33 references

Sorted by citations

Items 601–700 of 1,003

Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes
Golshayan, A., Jin, T., Maciejewski, J. P., Fu, A. Z., Bershadsky, B., Kattan, M. W., Kalaycio, M. E., & Sekeres, M. A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06546.x · Cited by 78
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
Komrokji, R. S., Corrales‐Yepez, M., Kharfan‐Dabaja, M. A., Ali, N. H. A., Padron, E., Rollison, D. E. M., Pinilla-Ibarz, J. A., Zhang, L., Epling‐Burnette, P. K., Lancet, J. E., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23303 · Cited by 78
Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Feenstra, J. D. M., Puda, A., Malcovati, L., Berg, T., Hofbauer, M., Stukalov, A., Klampfl, T., Harutyunyan, A. S., Gisslinger, H., Gisslinger, B., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23309 · Cited by 84
Recent advances in the understanding of inherited sideroblastic anaemia
Camaschella, C. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07290.x · Cited by 79
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Giagounidis, A. A. N., Fenaux, P., Mufti, G. J., Muus, P., Platzbecker, U., Sanz, G. F., Cripe, L. D., von Lilienfeld‐Toal, M., & Wells, R. A. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0449-0 · Cited by 77
Self-citation
Classification of myeloid neoplasms: a comparative review
McManus, P. M. (2005) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.2005.tb00042.x · Cited by 76
Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C
Fenaux, P., Gattermann, N., Seymour, J. F., Hellström‐Lindberg, E., Mufti, G. J., Dührsen, U., Gore, S. D., Ramos, F., Beyne‐Rauzy, O., List, A. F., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08082.x · Cited by 76
Self-citation
Advances in the prognostication and management of advanced MDS in children
Hasle, H., & Niemeyer, C. M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08724.x · Cited by 76
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes
Hartmann, J., Braulke, F., Sinzig, U., Wulf, G. G., Maas, J. H., Konietschke, F., & Haase, D. T. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.11.005 · Cited by 76
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes
Jabbour, E. J., Kantarjian, H. M., Koller, C. A., & Taher, A. T. (2008) · Cancer · doi:10.1002/cncr.23280 · Cited by 77
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Kerbauy, D. M. B., Chyou, F., Gooley, T. A., Sorror, M. L., Scott, B. L., Pagel, J. M., Myerson, D., Appelbaum, F. R., Storb, R. F., & Deeg, H. J. (2005) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.05.008 · Cited by 76
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
Silverman, L. R., & Mufti, G. J. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0347 · Cited by 76
Self-citation
Underreporting of Myeloid Malignancies by United States Cancer Registries
Craig, B. M., Rollison, D. E. M., List, A. F., & Cogle, C. R. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-1087 · Cited by 76
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
Porta, M. G. D., Jackson, C. H., Alessandrino, E. P., Rossi, M., Bacigalupo, A. P., Lint, M. T. V., Bernardi, M., Allione, B., Bosi, A., Guidi, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.88 · Cited by 76
Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia
Fernandez, T. D. S., Ornellas, M. H., de Carvalho, L. O., Tabak, D. G., & Abdelhay, E. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00056-4 · Cited by 76
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
Giagounidis, A. A. N., Germing, U., Strupp, C., Hildebrandt, B., Heinsch, M., & Aul, C. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1054-0 · Cited by 77
Self-citation
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
Sekeres, M. A., Kantarjian, H. M., Fenaux, P., Becker, P. S., Boruchov, A. M., Guerci‐Bresler, A., Hu, K., Franklin, J. L., Wang, Y., & Berger, D. P. (2010) · Cancer · doi:10.1002/cncr.25545 · Cited by 74
Self-citation
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
Huang, H.-H., Chen, F., Chou, W.-C., Hou, H., Ko, B., Lin, C.-T., Tang, J.-L., Li, C., Yao, M., Tsay, W., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5822-y · Cited by 58
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes
Nagata, Y., Zhao, R., Awada, H. K., Kerr, C. M., Mirzaev, I., Kongkiatkamon, S., Nazha, A., Makishima, H., Radivoyevitch, T., Scott, J. G., et al. (2020) · Blood · doi:10.1182/blood.2020005488 · Cited by 76
Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions–a review
BERNASCONI, P. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07245.x · Cited by 76
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
de Witte, T., Hagemeijer, A., Suciu, S., Belhabri, A., Delforge, M., Kobbe, G., Selleslag, D., Schouten, H. C., Ferrant, A., Biersack, H., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.019182 · Cited by 75
Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy
Leitch, H. A., Leger, C. S., Goodman, T. A., Wong, K. K., Wong, D. H. C., Ramadan, K. M., Rollins, M. D., Barnett, M. J., Galbraith, P. F., & Vickars, L. M. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.026 · Cited by 75
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Shaffer, B. C., Ahn, K. W., Hu, Z., Nishihori, T., Malone, A. K., Valcárcel, D., Grunwald, M. R., Bacher, U., Hamilton, B. K., Kharfan‐Dabaja, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0515 · Cited by 75
Mitochondrial DNA mutations in patients with myelodysplastic syndromes
Shin, M., Kajigaya, S., Levin, B. C., & Young, N. S. (2003) · Blood · doi:10.1182/blood-2002-06-1825 · Cited by 75
Blood Levels of Angiogenin and Vascular Endothelial Growth Factor Are Elevated in Myelodysplastic Syndromes and in Acute Myeloid Leukemia
Brunner, B., Gunsilius, E., Schumacher, P., Zwierzina, H., Gastl, G. A., & Stauder, R. (2002) · Stem Cells and Development · doi:10.1089/152581602753448586 · Cited by 75
Problematic WHO Reclassification of Myelodysplastic Syndromes
Members of the International MDS Study Group, & Head, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3447 · Cited by 75
Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes
Sokol, L., Cáceres, G., Volinia, S., Alder, H., Nuovo, G. J., Liu, C., McGraw, K. L., Clark, J., Sigua, C. A., Chen, D., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08581.x · Cited by 74
ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
Grosjean-Raillard, J., Tailler, M., Adès, L., Perfettini, J., Fabre, C., Braun, T., de Botton, S., Fenaux, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.457 · Cited by 74
Self-citation
Reserves, Functional, Immunoregulatory, and Cytogenetic Properties of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes
Klaus, M., Stavroulaki, E., Kastrinaki, M.-C., Fragioudaki, P., Giannikou, K., Psyllaki, M., Pontikoglou, C. G., Tsoukatou, D., Mamalaki, C., & Papadaki, H. Α. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0286 · Cited by 74
Chronic myelomonocytic leukemia in the light of the WHO proposals
Germing, U., Strupp, C., Knipp, S., Kuendgen, A., Giagounidis, A. A. N., Hildebrandt, B., Aul, C., Haas, R., Gattermann, N., & Bennett, J. M. (2007) · Haematologica · doi:10.3324/haematol.11051 · Cited by 74
Self-citation
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome
Chamuleau, M. E. D., Westers, T. M., van Dreunen, L., Groenland, J., Zevenbergen, A., Eeltink, C., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2009) · Haematologica · doi:10.3324/haematol.13612 · Cited by 74
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
Asayama, T., Tamura, H., Ishibashi, M., Kuribayashi-Hamada, Y., Onodera-Kondo, A., Okuyama, N., Yamada, A., Shimizu, M., Moriya, K., Takahashi, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21492 · Cited by 74
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age‐ and sex‐related differences
Nilsson, T., Höglund, M., Lenhoff, S., Rylander, L., Turesson, I., Westin, J., Mitelman, F., & Johansson, B. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04221.x · Cited by 74
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
Daver, N. G., Kantarjian, H. M., Ravandi, F., Estey, E. H., Wang, X., Garcia‐Manero, G., Jabbour, E. J., Konopleva, M. Y., O'Brien, S., Verstovšek, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.244 · Cited by 73
RIL , a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis
Boumber, Y., Kondo, Y., Chen, X., Shen, L., Gharibyan, V., Konishi, K., Estey, E. H., Kantarjian, H. M., Garcia‐Manero, G., & Issa, J. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3093 · Cited by 74
Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome
Kröger, N. M. (2012) · Blood · doi:10.1182/blood-2011-12-380162 · Cited by 75
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy
Dinardo, C. D., Daver, N. G., Jain, N., Pemmaraju, N., Bueso‐Ramos, C. E., Yin, C. C., Pierce, S. A., Jabbour, E. J., Cortes, J. E., Kantarjian, H. M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.8 · Cited by 73
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
Alessandrino, E. P., Porta, M. G. D., Malcovati, L., Jackson, C. H., Pascutto, C., Bacigalupo, A. P., Lint, M. T. V., Falda, M., Bernardi, M., Onida, F., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23458 · Cited by 73
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Sridhar, K. J., Ross, D. T., Tibshirani, R. J., Butte, A. J., & Greenberg, P. L. (2009) · Blood · doi:10.1182/blood-2009-08-236422 · Cited by 69
Self-citation
Myelodysplastic syndromes: from pathogenesis and prognosis to treatment
Fenaux, P. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.02.002 · Cited by 73
Self-citation
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro
Soenen, V., Touriño, C., Bonnet, M., Guillier, M., Flamant, S., Kotb, R. R., Bernheim, A., Bourhis, J.-H., Preudhomme, C., Fenaux, P., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208405 · Cited by 73
Self-citation
Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses
O’Keefe, C. L., Plasilova, M. L., Włodarski, M. W., Risitano, A. M., Rodriguez, A. R., Howe, E. C., Young, N. S., Hsi, E. D., & Maciejewski, J. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1960 · Cited by 73
The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
Hong, M., & He, G. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0002 · Cited by 83
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
de Swart, L., Crouch, S., Hoeks, M. P. A., Smith, A. G., Langemeijer, S. M. C., Fenaux, P., Symeonidis, A. S., Čermák, J., Hellström‐Lindberg, E., Stauder, R., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.212217 · Cited by 72
Self-citation
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes
Neukirchen, J., Blum, S., Kuendgen, A., Strupp, C., Aivado, M. A., Haas, R. R., Aul, C., Gattermann, N., & Germing, U. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01299.x · Cited by 72
Self-citation
Surface marker abnormalities in myelodysplastic syndromes.
Elghetany, M. T. (1998) · PubMed · Cited by 72
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan, A. M., Davidoff, A. J., Long, J. B., Hu, X. Y., Wang, R., Ma, X., Gross, C. P., Abel, G. A., Huntington, S. F., Podoltsev, N. A., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14305 · Cited by 72
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia
Byrne, M. T., Danielson, N., Sengsayadeth, S. M., Rasche, A., Culos, K., Gatwood, K. S., Wyatt, H., Chinratanalab, W., Dholaria, B., Ferrell, P. B., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25859 · Cited by 72
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Silverman, L. R., Greenberg, P. L., Raza, A., Olnes, M. J., Holland, J. F., Reddy, P. E., Maniar, M. L., & Wilhelm, F. E. (2014) · Hematological Oncology · doi:10.1002/hon.2137 · Cited by 71
Self-citation
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
Gangat, N., Strand, J. J., Lasho, T. L., Finke, C. M., Knudson, R. A., Pardanani, A. D., Li, C., Ketterling, R. P., & Tefferi, A. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.01003.x · Cited by 71
Azacitidine in the management of patients with myelodysplastic syndromes
Khan, C., Pathe, N., Fazal, S., LISTER, J. W., & Rossetti, J. M. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712464882 · Cited by 71
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes
Efficace, F., Gaïdano, G., Breccia, M., Criscuolo, M., Cottone, F., Caocci, G., Bowen, D., Lübbert, M., Angelucci, E., Stauder, R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13138 · Cited by 71
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Broliden, P. A., Dahl, I., Hast, R., Johansson, B., Juvonen, E., Kjeldsen, L., Porwit‐MacDonald, A., Sjoo, M., Tangen, J., Uggla, B., et al. (2006) · PubMed · Cited by 71
Low blood counts: immune mediated, idiopathic, or myelodysplasia
Valent, P. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.485.3798522 · Cited by 70
Peripheral blood MDS score: A new flow cytometric tool for the diagnosis of myelodysplastic syndromes
Cherian, S., Moore, J. S., Bantly, A. D., Vergilio, J., Klein, P. S., Luger, S. M., & Bagg, A. (2005) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20041 · Cited by 71
Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes
Ribatti, D., Polimeno, G., Vacca, A., Marzullo, A., Enrico Crivellato, B., Nico, B., Lucarelli, G. T., & Dammacco, F. (2002) · Leukemia · doi:10.1038/sj.leu.2402586 · Cited by 71
Current and emerging strategies for management of myelodysplastic syndromes
Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70
Deregulation of microRNAs in myelodysplastic syndrome
Rhyasen, G. W., & Starczynowski, D. T. (2011) · Leukemia · doi:10.1038/leu.2011.221 · Cited by 70
Expression and prognostic significance of Bcl‐2 family proteins in myelodysplastic syndromes
Boudard, D., Vasselon, C., Berthéas, M., Jaubert, J., Mounier, C., Reynaud, J., Viallet, A., Chautard, S., Guyotat, D., & Campos, L. (2002) · American Journal of Hematology · doi:10.1002/ajh.10108 · Cited by 70
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
Tam, C. S. L., Seymour, J. F., Prince, H. M., Kenealy, M. K., Wolf, M., Januszewicz, E. H., & Westerman, D. (2006) · PubMed · Cited by 70
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials
Yun, S., Vincelette, N. D., Abraham, I. L., Robertson, K. D., Fernández-Zapico, M. E., & Patnaik, M. M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0233-2 · Cited by 70
Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
Ross, S. D., Allen, I. E., Probst, C. A., Sercus, B., Crean, S. M., & Ranganathan, G. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1264 · Cited by 70
MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia
Guo, Y. P., Strickland, S. A., Mohan, S. R., Li, S., Bosompem, A., Vickers, K. C., Zhao, S., Sheng, Q., & Kim, A. S. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272680 · Cited by 69
Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes
Hejazi, M., Manser, A. R., Frobel, J., Kündgen, A., Zhao, X., Schönberg, K., Germing, U., Haas, R., Gattermann, N., & Uhrberg, M. (2015) · Haematologica · doi:10.3324/haematol.2014.118679 · Cited by 75
Classification and Prognostic Evaluation of Myelodysplastic Syndromes
Cazzola, M., Porta, M. G. D., Travaglino, E., & Malcovati, L. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.04.007 · Cited by 70
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System
Beran, M., Wen, S., Shen, Y., Onida, F., Jelı́nek, J., Cortes, J. E., Giles, F. J., & Kantarjian, H. M. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701216386 · Cited by 69
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review
Guariglia, R., Martorelli, M. C., Villani, O., Pietrantuono, G., Mansueto, G., D’Auria, F., Grieco, V., Bianchino, G., Lerose, R., Bochicchio, G. B., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.11.027 · Cited by 69
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
Kelaïdi, C., Park, S., Sapena, R., Beyne‐Rauzy, O., Coiteux, V., Vey, N., Stamatoullas, A., Choufi, B., Delaunay, J., Gourin, M. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.16 · Cited by 69
Self-citation
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
Nösslinger, T., Tüchler, H., Germing, U., Sperr, W. R., Krieger, O., Haase, D. T., Lübbert, M., Stauder, R., Giagounidis, A. A. N., Valent, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp264 · Cited by 69
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes
Fili, C. C., Malagola, M., Follo, M. Y., Finelli, C., Iacobucci, I., Martinelli, G., Cattina, F., Clissa, C., Candoni, A., Fanin, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3540 · Cited by 69
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
Nazha, A., Al-Issa, K., Hamilton, B. K., Radivoyevitch, T., Gerds, A. T., Mukherjee, S., Ademà, V., Zarzour, A., Abuhadra, N. K., Patel, B. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.266 · Cited by 68
Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová, Z., Žilovcová, S., Čermák, J., Řı́hová, H., Březinová, D., Dvořáková, R., Marková, M., Maaloufová, J., Sajdová, J., Březinová, J., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2003.11.020 · Cited by 69
Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression
Davis, R. E., & Greenberg, P. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00051-4 · Cited by 69
Self-citation
A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)‐Fc fusion protein in patients with myelodysplastic syndrome
Maciejewski, J. P., Ristiano, A. M., Sloand, E. M., Wisch, L. B., Geller, N. L., Barrett, J. A., & Young, N. S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03381.x · Cited by 69
Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome
Zou, J., Rollison, D. E. M., Boulware, D. C., Chen, D.-T., Sloand, E. M., Pfannes, L. V., Goronzy, J. J., Bai, F., Painter, J. S., Wei, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.14 · Cited by 69
Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older
Gupta, V. K., Daly, A. S., Lipton, J. H., Hasegawa, W. S., Chun, K., Kamel‐Reid, S., Tsang, R. W. C., Yi, Q., Minden, M. D., Messner, H. A., et al. (2005) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.06.006 · Cited by 68
Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course
McClure, R. F., Dewald, G., Hoyer, J. D., & Hanson, C. A. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01537.x · Cited by 68
A Comparative Review of Classification Systems in Myelodysplastic Syndromes (MDS)
Bennett, J. M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.06.021 · Cited by 68
Self-citation
Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting
Taussig, D. C., Davies, A. J., Cavenagh, J. D., Oakervee, H. E., Court, D. S., Kelsey, S., AMESS, J. A. L., Rohatiner, A. Z. S., Lister, T. A., & Barnett, M. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.057 · Cited by 68
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality
Jurado, M., Deeg, H. J., Storer, B. E., Anasetti, C., Anderson, J. E., Bryant, E. M., Chauncey, T. R., Doney, K., Flowers, M. E. D., Hansen, J. A., et al. (2002) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.2002.v8.pm11939606 · Cited by 68
Immune Mechanisms in Myelodysplastic Syndrome
Glenthøj, A. B., Ørskov, A. D., Hansen, J., Hadrup, S. R., O'Connell, C. L., & Grønbæk, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060944 · Cited by 69
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
Mishra, A., Corrales‐Yepez, M., Ali, N. E. A., Kharfan‐Dabaja, M. A., Padron, E., Zhang, L., Epling‐Burnette, P. K., Pinilla-Ibarz, J. A., Lancet, J. E., List, A. F., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23454 · Cited by 71
Dendritic Cells (DCs) Can Be Successfully Generated From Leukemic Blasts in Individual Patients With AML or MDS
Kremser, A., Dreyig, J., Grabrucker, C., Liepert, A., Kroell, T., Scholl, N., Schmid, C., Tischer, J., Kufner, S., Salih, H. R., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b8f4ce · Cited by 67
Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010
Dinmohamed, A. G., Visser, O. J., van Norden, Y., Huijgens, P. C., Sonneveld, P., van de Loosdrecht, A. A., & Jongen‐Lavrencic, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.002 · Cited by 68
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
Huang, T.-C., Ko, B., Tang, J.-L., Hsu, C., Chen, C.-Y., Tsay, W., Huang, S.-Y., Yao, M., Chen, Y., Shen, M.-C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405076 · Cited by 67
Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation
Hosokawa, K. T., Katagiri, T., Sugimori, N., Ishiyama, K., Sasaki, Y., Seiki, Y., Sato‐Otsubo, A., Sanada, M., Ogawa, S., & Nakao, S. (2012) · Haematologica · doi:10.3324/haematol.2011.061127 · Cited by 67
Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1
Brooimans, R. A., Kraan, J., van Putten, W., Cornelissen, J. J., Löwenberg, B., & Gratama, J. W. (2008) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20439 · Cited by 67
Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients
Romeo, M. A. S., Chauffaille, M. D. L., Silva, M. R. R., Kerbauy, D. M. B., & Kerbauy, J. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00047-4 · Cited by 67
Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome
Valcárcel, D., Ademà, V., Solé, F. G., Ortega, M., Nomdedeu, B., Sanz, G. F., Luño, E., del Cañizo, C., de la Serna, J., Ardanaz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6073 · Cited by 67
Self-citation
Association between Nasal Carriage of Staphylococcus Aureus and Infection in Liver Transplant Recipients
Bert, F., Galdbart, J., Zarrouk, V., Mée, J. L., Durand, F., Mentré, F., Belghiti, J., Lambert-zechovsky, N., & Fantin, B. (2000) · Clinical Infectious Diseases · doi:10.1086/317469 · Cited by 67
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series
Goncalves, I., Burbury, K., Michael, M., Iravani, A., Kumar, A. S. R., Akhurst, T. J., Tiong, I. S., Blombery, P. A., Hofman, M. S., Westerman, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04389-2 · Cited by 70
Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation
Shi, L., Zhao, Y., Fei, C., Guo, J., Jia, Y., Wu, D., Wu, L., & Chang, C. (2019) · Aging · doi:10.18632/aging.102409 · Cited by 68
Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes
Virchis, A. E., Koh, M., Rankin, P., Mehta, A. B., Potter, M. N., Hoffbrand, A. V., & Prentice, H. G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04728.x · Cited by 67
New Approaches to the Treatment of Myelodysplasia
List, A. F. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2004-39 · Cited by 67
Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?
Steensma, D. P., Dewald, G. W., Hodnefield, J. M., Tefferi, A., & Hanson, C. A. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00161-3 · Cited by 66
A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
Verburgh, E. R., Achten, R., Louw, V. J., Brusselmans, C., Delforge, M., Boogaerts, M. A., Hagemeijer, A., Vandenberghe, P., & Verhoef, G. E. G. (2007) · Leukemia · doi:10.1038/sj.leu.2404564 · Cited by 66
A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia
Quintás‐Cardama, A., Daver, N. G., Kim, H., Dinardo, C. D., Jabbour, E. J., Kadia, T. M., Borthakur, G. M., Pierce, S. A., Shan, J., Cárdenas-Turanzas, M., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.03.001 · Cited by 66
Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes
Chu, S.-C., Wang, T., Li, C., Kao, R.-H., Li, D., Su, Y., Wells, D. A., & Loken, M. R. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.02.016 · Cited by 66
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Delforge, M., Selleslag, D., Beguin, Y. P., Triffet, A., Mineur, P., Theunissen, K., Graux, C., Trullemans, F., Boulet, D., Eygen, K. V., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.003 · Cited by 66
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
Scott, L. J. (2016) · Drugs · doi:10.1007/s40265-016-0585-0 · Cited by 66

Authors: Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., & Bennett, J.
Affiliations: Tokyo Medical University (JP)
From the Hematology Divisions of Stanford University Medical Center, Stanford, CA; the Rochester Medical Center, Rochester, NY; the University of Chicago, Chicago, IL; Centre Hospitalier Universitaire, Lille, France; Hospital La Fe, Valencia, Spain; Hospital Vall d'Hebron, Barcelona, Spain; the Royal Bournemouth Hospital, Bournemouth, UK; the Tokyo Medical College, Tokyo, Japan; the Heinrich Heine University, Dusseldorf, Germany; and the King's College Hospital, London, UK.
ORCID: Greenberg, Peter
Cox, Christopher
Fenaux, Pierre
Morel, Pierre
Sanz, Guillermo
Sanz, Miguel
Oscier, David
Ohyashiki, Kazuma
Toyama, Keisuke
Mufti, Ghulam
Bennett, John
Venue: Blood
Publisher: American Society of Hematology
Published: 1997-03-15
Volume: 89
Issue: 6
Pages: 2079-2088
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood.v89.6.2079
OpenAlex: W187238933
Cited by: 4,427
References: 33
Citations by year: 2026: 45 · 2025: 69 · 2024: 93 · 2023: 124 · 2022: 131 · 2021: 155 · 2020: 167 · 2019: 144 · 2018: 174 · 2017: 226 · 2016: 183 · 2015: 205 · 2014: 232 · 2013: 253 · 2012: 256
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: myelodysplastic syndrome, prognostic score, International Prognostic Scoring System, risk stratification, bone marrow cytogenetics, acute myeloid leukemia transformation, bone marrow blasts, cytopenia, survival, del(5q), del(20q)
MeSH terms: Acute Disease, Adolescent, Adult, Age Factors, Aged, Bone Marrow, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Sex Factors, Multivariate Analysis, Survival Analysis, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks